Enveric Biosciences, Inc.

NasdaqCM:ENVB Stock Report

Market Cap: US$5.3m

Enveric Biosciences Management

Management criteria checks 2/4

Enveric Biosciences' CEO is Joseph Tucker, appointed in Sep 2021, has a tenure of 4.83 years. total yearly compensation is $879.54K, comprised of 53.7% salary and 46.3% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $4.40K. The average tenure of the management team and the board of directors is 4.8 years and 4 years respectively.

Key information

Joseph Tucker

Chief executive officer

US$879.5k

Total compensation

CEO salary percentage53.71%
CEO tenure4.8yrs
CEO ownership0.08%
Management average tenure4.8yrs
Board average tenure4yrs

Recent management updates

Recent updates

Analysis Article • Jul 02

An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% Undervalued

Key Insights The projected fair value for Enveric Biosciences is US$0.98 based on 2 Stage Free Cash Flow to Equity...
Seeking Alpha • Jul 25

Enveric Biosciences to raise $8M in stock offering for corporate use

Enveric Biosciences (NASDAQ:ENVB) announced Monday the direct stock offering to raise up to $8M priced at-the-market. This includes registered direct offering to issue 375,000 shares along with preferred investment options to purchase up to 375,000 additional shares at a combined price of $8 per unit. And a private placement for 625,000 shares in addition of preferred investment options to purchase up to 625,000 more shares at the same $8 apiece. The preferred investment options have an exercise price of $7.78 per share. The company said it intends to use the net proceeds from the offerings for working capital and general corporate purposes. Closing of the offering is expected on July 26, 2022. Also, Enveric amends the exercise price of some of its existing warrants' to $7.78 each down from initial $27.50 per share. It holds the option to purchase up to an aggregate of 122,000 shares of common stock. ENVB shares fell 22% premarket. Earlier: Enveric to spin out cannabinoid pipeline into a public company

CEO Compensation Analysis

How has Joseph Tucker's remuneration changed compared to Enveric Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$880kUS$472k

-US$12m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$9m

Dec 31 2024US$612kUS$459k

-US$10m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$15m

Dec 31 2023US$577kUS$451k

-US$17m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$826kUS$362k

-US$19m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$3mUS$92k

-US$49m

Compensation vs Market: Joseph's total compensation ($USD879.54K) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Joseph's compensation has increased whilst the company is unprofitable.

CEO

Joseph Tucker (57 yo)

4.8yrs
Tenure
US$879,541
Compensation

Dr. Joseph Edward Tucker, Ph D., is Independent Director of Lakewood-Amedex Biotherapeutics, Inc. from April 24, 2026. Dr. Tucker has been a Director of Enveric Biosciences, Inc. since September 16, 2021....

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Tucker
CEO & Director4.8yrsUS$879.54k0.082%
$ 4.4k
Kevin Coveney
Chief Financial Officer3.3yrsUS$678.45k0.056%
$ 3.0k
Peter Facchini
Chief Innovation Officer4.8yrsUS$253.17k0.025%
$ 1.4k
4.8yrs
Average Tenure
62yo
Average Age

Experienced Management: ENVB's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Tucker
CEO & Director4.8yrsUS$879.54k0.082%
$ 4.4k
Sheila DeWitt
Independent Director2.2yrsUS$83.65k0.71%
$ 38.1k
Stephen Stahl
Member of Scientific Advisory Board4yrsno datano data
Frank Pasqualone
Independent Director4yrsUS$101.15k0.72%
$ 38.3k
Maurizio Fava
Chairman of Scientific Advisory Board4yrsno datano data
Michael Liebowitz
Member of Scientific Advisory Board4yrsno datano data
John Krystal
Member of Scientific Advisory Board4yrsno datano data
Marcus Schabacker
Independent Non-Employee Director5.6yrsUS$87.65k0.72%
$ 38.3k
George Kegler
Independent Non-Employee Director5.6yrsUS$94.65k0.72%
$ 38.3k
Michael Webb
Independent Chairman of the Board4.1yrsUS$210.65kno data
4.0yrs
Average Tenure
66yo
Average Age

Experienced Board: ENVB's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 09:32
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enveric Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.